Evelo dealt an­oth­er blow with a PhII fail, plans for strate­gic al­ter­na­tives

Evelo Bio­sciences is ex­plor­ing strate­gic al­ter­na­tives for its mid-stage pso­ri­a­sis treat­ment af­ter it re­port­ed that an­oth­er pso­ri­a­sis drug failed a Phase II clin­i­cal tri­al.

Since the mar­ket opened, Evelo’s stock $EV­LO has plum­met­ed by about 46% to $1.48 per share.

The com­pa­ny said Tues­day that the Phase II tri­al of EDP2939, a mi­cro­bial ex­tra­cel­lu­lar vesi­cle that is de­liv­ered oral­ly to pa­tients, did not achieve its pri­ma­ry end­point af­ter 16 weeks of dai­ly treat­ment com­pared to a place­bo. The tri­al in­ves­ti­gat­ed how many pa­tients showed a 50% im­prove­ment in mod­er­ate pso­ri­a­sis af­ter treat­ment with EDP2939 us­ing the Pso­ri­a­sis Area and Sever­i­ty In­dex score. Evelo stopped de­vel­op­ment of EDP2939.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER